ArticleUpdates in surgery2026
Characteristics and predictors of survival outcomes of patients with large pathology-defined T1b hepatocellular carcinoma undergoing resection.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
As tumor size increases, the risk of microscopic vascular invasion (MVI) and satellite nodules increases for patients with hepatocellular carcinoma (HCC). However, large pathology-defined T1b (pT1b) HCC (i.e., single tumor > 5.0 cm without MVI) has been noted in a small proportion of patients with HCC undergoing liver resection (LR). We aimed to determine the characteristics and predictors of survival outcomes of this special population. We consecutively included 126 patients with HCC at pathological stage T1b N0M0 of the 8th edition of the American Joint Committee on Cancer staging and a tumor size of > 5.0 cm who underwent LR between 2007 and 2021 at our institution. Variables based on a priori selection, i.e., alpha-fetoprotein (AFP) level, cirrhosis status, resection extent, and tumor differentiation, were included in a multivariate analysis using the Cox proportional hazards model. Of the 126 patients, 27 (21.4%) had cirrhosis, 3 (2.4%) showed poor tumor differentiation, 88 (70.0%) underwent major resection, and 40 (31.7%) had an AFP level of ≥ 20 ng/ml. Five-year overall survival was 78.8% (95% confidence interval [CI] = 78.4%-79.2%); 5-year recurrence-free survival was 60.3% (95% CI = 59.8%-60.8%). Multivariate analysis showed that poor tumor differentiation was the only factor associated with mortality (hazard ratio [HR] = 38.46; 95% CI = 7.577-195.27; p < 0.001) and recurrence (HR = 9.153; 95% CI = 2.371-35.331; p = 0.001). The survival outcomes of this special population were good. About 80% of these patients were non-cirrhotic. Poor tumor differentiation was the only factor associated with survival outcomes.
Indexed as
Identifiers
42635712What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.